Advances in molecular,genetic and immune signatures of gastric cancer:Are we ready to apply them in our patients' decision making?

查看全文 作　　者：Stavros [1]Gkolfinopoulos;Demetris [1]Papamichael;Konstantinos [2]Papadimitriou;Panos [1]Papanastasopoulos;Vassilios [3]Vassiliou;Panteleimon [1]Kountourakis 机构地区：[1]Demetris Papamichael,Panos Papanastasopoulos,Panteleimon Kountourakis,Department of Medical Oncology,BOC Oncology Center,Nicosia 2006,Cyprus;[2]Department of Medical Oncology,University Hospital of Antwerp,Antwerp 2650,Belgium;[3]Department of Radiation Oncology,BOC Oncology Center,Nicosia 2006,Cyprus 出　　处：《World Journal of Gastrointestinal Oncology》索引2018年第10卷第7期,共12页 摘　　要：In the last few years we have witnessed a vast expansion of our knowledge regarding the molecular and genetic profile of gastric cancer.The molecular subtypes described have shed light on the pathogenesis of the disease,thus prompting the development of new therapeutic strategies and favoring a more individualized approach for treatment.Most of the clinical trials for so called targeted therapies could be considered,at best,partially successful.In addition,checkpoint inhibitors ha-ve recently been added to our armamentarium in later stages of the disease,and combinations with chemotherapy and targeted agents are currently under development.In view of the rapid advances of molecular oncology,a new challenge for the clinical oncologist arises: The appropriate patient selection for each new therapy,which can be made possible only through the implementation of predictive biomarkers in our therapy decision making. 关 键 词：Gastric CANCER CANCER GENOME ATLAS Asian CANCER Research Group Targeted therapy